Wells Fargo
BXRX

Wells Fargo’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Wells Fargo’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-53
Closed -$20 – 7858
2023
Q3 		$20 Buy
53
+9
+20% +$5 ﹤0.01% 7210
2023
Q2 		$51 Buy
44
+41
+1,367% +$39 ﹤0.01% 7050
2023
Q1 		$5 Hold
3
– – ﹤0.01% 7601
2022
Q4 		$10 Buy
3
+2
+200% +$12 ﹤0.01% 7378
2022
Q3 		$0 Hold
1
– – ﹤0.01% 7943
2022
Q2 		$0 Buy
+1
New +$47 ﹤0.01% 8040
2022
Q1 		– Sell
-1
Closed -$185 – 8337
2021
Q4 		$0 Hold
1
– – ﹤0.01% 8222
2021
Q3 		$1K Sell
1
-2
-67% -$1.74K ﹤0.01% 6889
2021
Q2 		$3K Buy
3
+2
+200% +$2.62K ﹤0.01% 6504
2021
Q1 		$2K Sell
1
-1
-50% -$2K ﹤0.01% 6668
2020
Q4 		$2K Sell
2
-36
-95% -$73.7K ﹤0.01% 6307
2020
Q3 		$147K Sell
38
-22
-37% -$99.5K ﹤0.01% 5108
2020
Q2 		$348K Sell
60
-53
-47% -$254K ﹤0.01% 4581
2020
Q1 		$393K Buy
113
+100
+769% +$944K ﹤0.01% 4220
2019
Q4 		$129K Buy
+13
New +$111K ﹤0.01% 5184

Wells Fargo's BXRX Position: Q4 2023 in Review

Wells Fargo sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q4 2023, closing a stake of 53 shares — an estimated $20 sold.

Wells Fargo first reported a position in BXRX in Q4 2019 and held it in 15 quarters. The position peaked at $393K in Q1 2020. 2 funds tracked by Wall St. Rank hold BXRX as of Q4 2023.

  • Wells Fargo reported no remaining Baudax Bio, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Wells Fargo sold 53 Baudax Bio, Inc. Common Stock shares in Q4 2023, an estimated $20.
  • Wells Fargo first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 15 quarters.
  • Wells Fargo's Baudax Bio, Inc. Common Stock position peaked at $393K in Q1 2020.
  • 2 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q4 2023.

Based on Wells Fargo's 13F filing for Q4 2023, filed 9 Feb 2024.